Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter cohort study evaluating long-term gadolinium deposition
2012-000941-11Phase 4Completed
- Sponsor
- Bracco Imaging
- Start
- Feb 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gadobenate dimeglumine and gadoteridol in nephrogenic systemic fibrosis (NSF) (2 cohorts), sponsored by Bracco Imaging. Primary endpoints: Long-term gadolinium deposition in bone tissue and Long-term gadolinium deposition in skin tissue. Started Feb 2013; status: completed.
02
Drugs
gadobenate dimegluminegadoteridol
03
Conditions
nephrogenic systemic fibrosis (NSF)
Beyond the preview
Go deeper on 2012-000941-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000941-11.